M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD
Launched by OSPEDALE SANTA CROCE-CARLE CUNEO · Apr 5, 2022
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
Introduction
Age-related macular degeneration (AMD) is a complex eye disorder and the most common macular disease affecting millions of aged people in developed countries, with an estimation that the number of AMD patients will be increased to 196 million in 2020, 288 million in 2040. Vision loss, central scotomas, and metamorphopsia are the hallmark signs in patients with macular diseases. Metamorphopsia can be defined as a deformation of seen rectilinear lines due to photoreceptor separation/location and it is a typical but not exclusive sign of retinal disease. The most effective method...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of neovascular age-related macular degeneration with active CNV on fluorangiographic examination
- • Visual acuity (VA) equal to or greater than 1.0 logMAR
- • Written informed consent
- • Age over 50.
- Exclusion Criteria:
- • Prior intravitreal injection or intraocular surgery
- • Major ocular diseases such as amblyopia, glaucoma, or strabismus, and refracting errors greater than 4D.
About Ospedale Santa Croce Carle Cuneo
Ospedale Santa Croce-Carle Cuneo is a renowned healthcare institution located in Cuneo, Italy, dedicated to providing high-quality medical services and advancing clinical research. As a prominent clinical trial sponsor, the hospital is committed to facilitating innovative studies that enhance patient care and contribute to the medical community's understanding of various health conditions. With a focus on ethical practices, patient safety, and rigorous scientific methodologies, Ospedale Santa Croce-Carle Cuneo plays a vital role in the development of new therapies and treatment approaches, fostering collaboration among healthcare professionals, researchers, and academic institutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cuneo, Piedmont, Italy
Patients applied
Trial Officials
Silvia Violante, MD
Study Chair
OSCroceCarle, +39 0171 641571
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials